Join the club for FREE to access the whole archive and other member benefits.

Antoni Ribas

Professor of medicine, surgery, and molecular and medical pharmacology at UCLA

Antoni Ribas is professor of medicine, surgery, and molecular and medical pharmacology at the University of California Los Angeles (UCLA), director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC) and director of the Parker Institute for Cancer Immunotherapy (PICI) Center at UCLA.

His research is focused on laboratory and clinical studies to address primary and acquired resistance to immunotherapy and targeted therapies for melanoma, and in the development of gene-engineered adoptive T cell transfer therapies for cancer. He has been instrumental in the clinical development of several agents approved by the FDA, including the first anti-PD-1 pembrolizumab (Keytruda), two combinations of BRAF and MEK inhibitors vemurafenib (Zelboraf) and cobimetinib (Cotellic), dabrafenib (Tafinlar) and trametinib (Mekinist), and was involved in the development of the first CD19 CAR for lymphoma axicabtagene ciloleucel (Yescarta). He is a past president of the American Association for Cancer Research (AACR), an elected Fellow of the AACR Academy, the Royal Academy of Medicine of Catalonia, the American Society of Clinical Investigation, and the National Academy of Medicine.

Visit website:


See also: Academia University of California, Los Angeles (UCLA) - Public land-grant research university

Details last updated 15-Jul-2023

Antoni Ribas News

CRISPR gene-editing technology boosts cancer-fighting immune cells

BBC - 11-Nov-2022

Personalized T-cell therapy for untreatable cancers - further studies needed to test the dose and effectiveness